Skip to content
Dose Brief
Menu

Briefs · 40 providers

GLP-1 provider reviews

Compare our rated directory using the Brief Score — price stability, supply reliability, transparency and access.

More provider reviews

Browse all 150

Costs, program terms and sources. These reviews have not received a Brief Score.

Showing 1–40 of 546 rated-directory entries. Most recent verification in the ranking: .

Grade A

The strongest on price stability and supply.

Grade B

Solid providers with a trade-off worth reading first.

Status assessments

Current prescription availability needs confirmation; retained scores describe earlier listings.

Brief Scores are our editorial judgment per the methodology; facts reflect each provider's public disclosures at last check. A commission never changes a score, and it never softens what we write about a provider. What it does move is position: this index runs in ranking order, and providers we have a commercial relationship with sit ahead of providers we do not. Weigh the write-up, not the slot — see our disclosure. Not medical advice.

The desk's No. 1 · 94/100

CoreAge Rx

CoreAge publishes different starting offers across its pages; the advertised annual rates require a full year paid upfront.

Semaglutide
From $79/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($948 at that starting rate); main product page separately advertises from $99/mo
Tirzepatide
From $129/mo on the annual-plan landing offer, based on a 12-month plan paid in full ($1,548 at that starting rate); main product page separately advertises from $149/mo
Visit CoreAge Rx ↗
Full brief →Ad disclosure — we may earn a commission.

Shopping on price?

See every provider with its price direction and the note behind it.

Open the ranking →